Clinical Scorecard: ADHD Drug CTx-1301 Receives Complete Response Letter

At a Glance

Key Highlights

• CTx-1301 received a Complete Response Letter from the FDA.
• FDA's feedback focused on Chemistry, Manufacturing and Controls (CMC) requests.
• No current concerns related to clinical safety or efficacy were identified.
• CTx-1301 is designed for once-daily administration with three timed releases.
• The product is being evaluated under the FDA’s 505(b)(2) pathway.

Guideline-Based Recommendations

Diagnosis

• ADHD diagnosis should follow established clinical criteria.

Management

• CTx-1301 remains investigational and is not yet approved for ADHD.

Monitoring & Follow-up

• Monitor for efficacy and safety once approved.

Risks

• No specific risks identified in the FDA's response.

Patient & Prescribing Data

Patients with ADHD awaiting treatment options.

CTx-1301 aims to provide a controlled release of medication throughout the day.

Clinical Best Practices

• Follow FDA guidelines for investigational drugs.
• Ensure comprehensive evaluation of ADHD treatments.

Related Resources & Content

• Cingulate Announcement